Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory.
From Fredun Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years.
- Vintage business expected to grow sustainably at around 15% CAGR for the next 7 to 9 years driven by registrations and existing channels.
- New age businesses (Pet Care, Nutraceuticals, Mobility) are growing month-on-month with detailed 3 to 7-year plans for each vertical.
- Wagr e-commerce platform aims for a multi-million dollar monthly revenue in 5 to 7 years.
- By FY'29, management targets INR 90 crores PAT, with potential for higher performance depending on market conditions.
- Pet Care division to significantly scale with expansion into 52 countries; strong domestic bases being built to support exports.
- Continual product innovation and new SKUs launch to drive working capital needs and revenue growth.
- Expansion in manufacturing capacity and distribution enhancing scalability and supporting growth across product lines.
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution.
- Recent fundraising will be used as growth capital to accelerate sustainable growth in new age businesses towards 2029-2030.
- Planned investments include INR4-5 crores over the next 18-24 months and another INR5-7 crores later for the Wagr e-commerce platform to align and promote sales.
- The company is expanding manufacturing capacity with a state-of-the-art facility at Palghar and adding contract manufacturing locations to support product portfolio growth.
- Capex also includes infrastructure to increase production, especially for nutraceuticals, mobility, cosmetics, and pet care products.
- The acquisition of Wagr.ai was a zero-cash cost deal, focusing investment on platform development rather than acquisition price.
- Hiring and building a robust human resource infrastructure across different brands and verticals is a key ongoing strategic investment.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals has received an "unbelievable" and "crazy phenomenal" response for their Snacky Jain product.
- The order book for Snacky Jain has surpassed their initial expectations.
- Due to high demand, they had to revisit manufacturing and procurement plans.
- Snacky Jain is expected to be in stores across certain geographies by the end of November 2025.
- Within the next 6 months, it is planned to be available in most parts of India.
- They are receiving multiple daily requests for entire stock purchases from customers.
- Plans to launch more variants of Snacky Jain targeting different nutritional and health needs (gut health, mobility health, geriatric dogs, young dogs) to cater to the demand.
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharmaceutical Industries Ltd (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q2 FY26 results?
Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.